Australian Health Practitioner Regulation Agency - Ahpra

Happy NAIDOC Week!

This year’s theme, 50 Years of Deadly, celebrates five decades of strength, resistance, leadership and achievements of Aboriginal and Torres Strait Islander Peoples.

It's a time to come together, listen, learn, unlearn and engage with Aboriginal and Torres Strait Islander communities as we all work towards a culturally safe health system.

We encourage everyone to take part in local NAIDOC Week events and engage with the learning resources below to deepen your understanding of Aboriginal and Torres Strait Islander histories, cultures and achievements.

https://ab.co/4wxgHWl

This is a joint statement from the TGA and Australia’s Chief Medical Officer on concerns regarding the public health risks associated with unapproved peptide products.

Australia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.

Reports received by TGA, along with hospitalisation data from states and territories, have identified serious adverse effects associated with the use of unapproved peptides. These include:

- liver damage
- severe allergic reaction requiring hospitalisation, and
- inflammation and other health complications requiring medical attention.

We strongly advise Australians not to purchase and use unapproved peptide products, particularly those obtained online or from overseas. Consumers should seek advice from qualified healthcare professionals and use only products supplied through Australian pharmacies.

Many of these products are supplied as powders or injections in poorly labelled or unmarked vials, making it difficult or impossible to verify their ingredients, or the safety of how they have been manufactured. This further presents significant risks to consumer safety, including potential contamination, dosing uncertainty, and exposure to unknown or harmful substances.

Find out more: https://www.tga.gov.au/news/media-releases/concerns-regarding-public-health-risks-associated-unapproved-peptide-products

Ahpra and Australia’s Special Envoy to Combat Antisemitism have issued a joint statement.

Read more: https://www.ahpra.gov.au/News/2026-06-17-Eliminating-antisemitism-in-healthcare.aspx